reports
- Sean Conroy
EyeGate Pharmaceuticals - OBG pivotal study recruitment on schedule
EyeGate’s Ocular Bandage Gel (OBG) is progressing in its ongoing pivotal study in corneal wound healing following photorefractive keratectomy (PRK) surgery. The firm recently met its 75% recruitment target (planned n=260 patients) and data are expected by YE19. If positive, it should lead to a market approval filing in H120. EyeGate will shortly begin a follow-on pilot study in punctate epitheliopathies (PE), a much larger indication that is related to dry eye disease (DED). Prior OBG PRK stud...
EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in...
EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will also host one-on-one meetings through BIO CEO & Investor conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology ...
EyeGate Pharmaceuticals Announces Meeting Date with FDA
EyeGate Pharmaceuticals Announces Meeting Date with FDA WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on Wednesday, March 20th, 2019 to discuss EyeGate’s de novo application strategy for its Ocular Bandage Gel (OBG) product, which will cover the clinical plan, data to date, and potential submission timelines. EyeGate’s OBG platform, a unique cross-linked hyaluronic acid compound, has potentially broad applications in ma...
- Pooya Hemami
EyeGate Pharmaceuticals - Positive signals in OBG PRK and PE studies
EyeGate reported data in its Ocular Bandage Gel (OBG) studies in punctate epitheliopathies (PE) and in corneal wound healing following bilateral photorefractive keratectomy (PRK) surgery. The PRK study showed improved wound healing and the PE trial showed improvement in patient symptoms. EyeGate will meet with the FDA to discuss whether the existing data are sufficient for a 510(k) de novo regulatory filing.
EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results a...
EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended September 30, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “The third quarter of 2018 was a transformative quarter for EyeGate, with the Company receiving FDA approval for two IDE submissions for our Ocular Bandage Gel ...
EyeGate Pharma Announces Positive Results in Second PRK Study
EyeGate Pharma Announces Positive Results in Second PRK Study Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of care. Daniel S. Durrie, M.D., Founder, Durrie Vision in Overland Park, KS, said, “This is the first time I have seen a product hea...
EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy S...
EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. Randall J Olson, M.D., CEO and Chair of the Department of Ophthalmology and Visual Sciences of the John A. Moran Eye Center, University of Utah, SLC, said, “A product that achieves symptomology results ...
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreemen...
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the execution of a license agreement with SentrX™ Animal Care, Inc., a veterinary medical device company that develops and manufactures veterinary wound care products. Under the agreement, EyeGate will in-license the rights to trade-secrets and k...
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nas...
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company has been granted an additional 180 days to comply with Nasdaq’s continued listing rules. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1 per share. With the extension granted, EyeGate has...
EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot ...
EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today that patient enrollment is complete in the next two pilot studies using the Hyaluronic Acid (HA) polymer for both photorefractive keratectomy (PRK) and punctate epitheliopathies (PE). The Company is also on track to report top-line data from both studies in the f...
EyeGate Announces Randomization of First Patients in Study for Punctat...
EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first three patients have been randomized in its study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to reduce corneal staining – a sign of ocular surface damage - in patients with punctate epitheliopathies (PE) due to pathologi...
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Ant...
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced top-line results from its Phase 3 study evaluating the safety and efficacy of EGP-437 delivered through the EyeGate® II Drug Delivery System (EGDS) in patients with non-infectious anterior segment uveitis. Although EGP-437 showed clinical efficacy, defined...
EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright...
EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company will present at the upcoming H.C. Wainwright 20th Annual Global Investment Conference, being held on September 4-6, 2018 at the St. Regis Hotel in New York City. Stephen From, President and Chief Executive Office...
EyeGate Announces Enrollment of First Patient in PRK Pilot Study
EyeGate Announces Enrollment of First Patient in PRK Pilot Study WALTHAM, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) surgery. Barbara Wi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.